CN102775429B - 不饱和去甲基斑蝥酸银配聚物的制备和用途 - Google Patents
不饱和去甲基斑蝥酸银配聚物的制备和用途 Download PDFInfo
- Publication number
- CN102775429B CN102775429B CN201210283120.8A CN201210283120A CN102775429B CN 102775429 B CN102775429 B CN 102775429B CN 201210283120 A CN201210283120 A CN 201210283120A CN 102775429 B CN102775429 B CN 102775429B
- Authority
- CN
- China
- Prior art keywords
- polymers
- cantharidic acid
- demethyl
- silver
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229930008399 cantharidic acid Natural products 0.000 title claims abstract description 10
- 229920000642 polymer Polymers 0.000 title claims abstract description 9
- -1 Unsaturated demethyl Cantharidic acid Chemical compound 0.000 title claims abstract description 7
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- 229910052709 silver Inorganic materials 0.000 title abstract description 5
- 239000004332 silver Substances 0.000 title abstract description 5
- BQCADISMDOOEFD-UHFFFAOYSA-N silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 title description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 7
- 201000005296 lung carcinoma Diseases 0.000 claims abstract description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 229920001795 Coordination polymer Polymers 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 abstract description 4
- 230000005712 crystallization Effects 0.000 abstract description 4
- 150000001450 anions Chemical class 0.000 abstract description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 2
- 229960004316 cisplatin Drugs 0.000 abstract description 2
- 150000004682 monohydrates Chemical class 0.000 abstract description 2
- 238000006116 polymerization reaction Methods 0.000 abstract description 2
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 abstract description 2
- 150000001336 alkenes Chemical class 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 231100000171 higher toxicity Toxicity 0.000 abstract 1
- 231100000053 low toxicity Toxicity 0.000 abstract 1
- 210000004027 cells Anatomy 0.000 description 12
- JAABVEXCGCXWRR-FBXFSONDSA-N Rel-Norcantharidin Chemical compound C1C[C@H]2[C@@H]3C(=O)OC(=O)[C@@H]3[C@@H]1O2 JAABVEXCGCXWRR-FBXFSONDSA-N 0.000 description 7
- 229910052751 metal Inorganic materials 0.000 description 6
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(I) nitrate Inorganic materials [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 6
- 239000002184 metal Substances 0.000 description 5
- PLBHSZGDDKCEHR-LFYFAGGJSA-N methylprednisolone acetate Chemical group C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 PLBHSZGDDKCEHR-LFYFAGGJSA-N 0.000 description 5
- NMTNUQBORQILRK-XCVPVQRUSA-N cantharidic acid Chemical compound C1C[C@@H]2[C@](C(O)=O)(C)[C@@](C)(C(O)=O)[C@H]1O2 NMTNUQBORQILRK-XCVPVQRUSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- 206010065553 Bone marrow failure Diseases 0.000 description 3
- DHZBEENLJMYSHQ-XCVPVQRUSA-N Cantharidin Chemical compound C([C@@H]1O2)C[C@@H]2[C@]2(C)[C@@]1(C)C(=O)OC2=O DHZBEENLJMYSHQ-XCVPVQRUSA-N 0.000 description 3
- 229940095758 Cantharidin Drugs 0.000 description 3
- 229930008397 cantharidin Natural products 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000000259 anti-tumor Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000001124 Body Fluids Anatomy 0.000 description 1
- 210000001185 Bone Marrow Anatomy 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- 210000000265 Leukocytes Anatomy 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 229960004857 Mitomycin Drugs 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N N'-amino-N-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229940026778 Other chemotherapeutics in ATC Drugs 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 208000008425 Protein Deficiency Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229960004528 Vincristine Drugs 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000000973 chemotherapeutic Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 201000011231 colorectal cancer Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000002607 hemopoietic Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000000474 nursing Effects 0.000 description 1
- 201000001539 ovarian carcinoma Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210283120.8A CN102775429B (zh) | 2012-08-10 | 不饱和去甲基斑蝥酸银配聚物的制备和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210283120.8A CN102775429B (zh) | 2012-08-10 | 不饱和去甲基斑蝥酸银配聚物的制备和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102775429A CN102775429A (zh) | 2012-11-14 |
CN102775429B true CN102775429B (zh) | 2016-11-30 |
Family
ID=
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1500789A (zh) * | 2002-11-19 | 2004-06-02 | 北京大学 | 含去甲基斑蝥酸根(DCA)的铜(Ⅱ)、镓(Ⅲ)及稀土离子(Ln3+)混配配合物ML(DCA) |
CN1686102A (zh) * | 2005-04-08 | 2005-10-26 | 中山大学 | 斑蝥素衍生物在制备抗肿瘤药物中的应用 |
CN1861610A (zh) * | 2005-05-11 | 2006-11-15 | 武德柱 | 去甲斑蝥素-钕的合成 |
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1500789A (zh) * | 2002-11-19 | 2004-06-02 | 北京大学 | 含去甲基斑蝥酸根(DCA)的铜(Ⅱ)、镓(Ⅲ)及稀土离子(Ln3+)混配配合物ML(DCA) |
CN1686102A (zh) * | 2005-04-08 | 2005-10-26 | 中山大学 | 斑蝥素衍生物在制备抗肿瘤药物中的应用 |
CN1861610A (zh) * | 2005-05-11 | 2006-11-15 | 武德柱 | 去甲斑蝥素-钕的合成 |
Non-Patent Citations (2)
Title |
---|
"A two-dimensional undulating AgI coordination polymer constructed of Ag-C and Ag-O bonds:poly[[[μ3-(5,6-η):κO2:κO2-(±)-(1S,2S,3R,"A two-dimensional undulating AgI coordination polymer constructed of Ag-C and Ag-O bonds:poly... monohydrate";F Y Wang等;《Acta Crystallographica Section C》;20110604;第67卷(第7期);m218-m220 * |
"Unsymmetrical coordinated Ag(I)-olefin complex based on ...Synthesis, structure and electrocatalytical property";20120202;《Inorganic Chemistry Communications》;20120202;第19卷;第39-42页 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kioseoglou et al. | The chemistry and biology of vanadium compounds in cancer therapeutics | |
Şahin-Bölükbaşı et al. | Novel Silver-NHC complexes: Synthesis and anticancer properties | |
CN103450281A (zh) | 一种1-氮杂苯并蒽酮-铂(ii)配合物及其合成方法和应用 | |
Cheng et al. | Synthesis, structure and antitumor studies of a novel decavanadate complex with a wavelike two-dimensional network | |
Hoffmann et al. | Rational design of dicarboxylato platinum (II) complexes with purine-mimetic ligands as novel anticancer agents | |
AU7503800A (en) | An antitumor derivative of double dicarboxylic acid diaminoplatin complex and the pharmaceutical composition thereof | |
CN108774270A (zh) | 靶向于人肺癌耐药细胞的索拉非尼抗肿瘤铂(ii)配合物及其制备方法与应用 | |
CN102731580B (zh) | 一种双核铂(ii)-双膦酸类配合物及其制备方法和应用 | |
CN105713047A (zh) | 一类铂(ii)配合物及其制备方法和用途 | |
JP6730958B2 (ja) | ベンゼンポリカルボン酸化合物及びその薬剤としての使用 | |
CN105481902B (zh) | 以磷酸二氢根为轴向配体的铂(iv)抗癌化合物 | |
CN102775429B (zh) | 不饱和去甲基斑蝥酸银配聚物的制备和用途 | |
CN108409781B (zh) | 一种六钒酸-l-丙氨酸叔丁酯衍生物及其制备方法与应用 | |
CN107488198B (zh) | 一种色胺酮铂配合物及其合成方法与应用 | |
CN113735909B (zh) | 一种Lindqvist型钨钒酸三羟甲基乙烷衍生物及其制备方法和应用 | |
Griffith et al. | Novel platinum pyridinehydroxamic acid complexes: Synthesis, characterisation, X-ray crystallographic study and nitric oxide related properties | |
CN110698383B (zh) | 苯偶酰腙-3-乙酰基吲哚的结构、合成及用途 | |
CN104086597B (zh) | 以3-氧代-环丁烷-1,1-二羧酸根为配体的铂(ii)抗肿瘤化合物 | |
CN104151304B (zh) | 一种三唑类化合物 | |
CN102924525B (zh) | 一种新型钌(ii)多吡啶配合物的合成方法 | |
CN104557990A (zh) | 氨基多羧酸邻菲罗啉锌配合物的合成及其在抗肿瘤药物中的应用 | |
CN102775429A (zh) | 不饱和去甲基斑蝥酸银配聚物的制备和用途 | |
CN102603805A (zh) | 具有抗肿瘤活性的铂(ii)配合物及其制备方法 | |
CN109692170A (zh) | 一种抗乳腺癌药物 | |
CN106883271B (zh) | 抗肿瘤活性的ONS三齿配体Pt(II)配合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
CB02 | Change of applicant information |
Address after: 250353 University Road, Science Park, West New Town University, Ji'nan, Shandong Applicant after: Qilu University of Technology Address before: 250353 New Town University, Science Park, University Road, Shandong Light Industries College, Ji'nan, Shandong Applicant before: Shandong Institute of Light Industry |
|
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Tan Xuejie Inventor after: Shi Yan Inventor after: Xing Dianxiang Inventor after: Liu Yun Inventor before: Tan Xuejie Inventor before: Xing Dianxiang Inventor before: Liu Yun |
|
CB03 | Change of inventor or designer information |
Inventor after: Tan Xuejie Inventor after: Wang Chao Inventor after: Shi Yan Inventor after: Xing Dianxiang Inventor after: Liu Yun Inventor before: Tan Xuejie Inventor before: Shi Yan Inventor before: Xing Dianxiang Inventor before: Liu Yun |
|
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20161130 Termination date: 20170810 |